{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:07Z","timestamp":1792012327819,"version":"4.4.0"},"publisher-location":"Berlin, Heidelberg","reference-count":21,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642544897","type":"print"},{"value":"9783642544903","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-3-642-54490-3_16","type":"book-chapter","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T09:36:51Z","timestamp":1398159411000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ruxolitinib"],"prefix":"10.1007","author":[{"given":"Heiko","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"issue":"13","key":"16_CR1","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901","journal-title":"Blood"},{"issue":"9","key":"16_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012a) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798","journal-title":"N Engl J Med"},{"key":"16_CR4","doi-asserted-by":"crossref","unstructured":"Harrison CN, Gisslinger H, Miller CB et al (2012b) Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50\u00a0\u00d7\u00a0109\/L and 99\u00a0\u00d7\u00a0109\/L. Blood 120 (abstract 177) (ASH Annual Meeting Abstracts)","DOI":"10.1182\/blood.V120.21.177.177"},{"issue":"7037","key":"16_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144\u20131148","journal-title":"Nature"},{"issue":"24","key":"16_CR6","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","volume":"121","author":"J Mascarenhas","year":"2013","unstructured":"Mascarenhas J, Hoffman R (2013) A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121(24):4832\u20134837","journal-title":"Blood"},{"issue":"3","key":"16_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cell.2007.10.033","volume":"131","author":"C Mertens","year":"2007","unstructured":"Mertens C, Darnell JE Jr (2007) SnapShot: JAK-STAT signaling. Cell 131(3):612","journal-title":"Cell"},{"issue":"2","key":"16_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","volume":"11","author":"RA Mesa","year":"2012","unstructured":"Mesa RA, Yasothan U, Kirkpatrick P (2012) Ruxolitinib. Nat Rev Drug Discov 11(2):103\u2013104","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"16_CR900","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V et al (2013)\u00a0Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31(10):1285--1292","journal-title":"J Clin Oncol"},{"issue":"15","key":"16_CR9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109\u20133117","journal-title":"Blood"},{"issue":"6","key":"16_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T et al (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809\u2013818","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"16_CR11","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"AD Shilling","year":"2010","unstructured":"Shilling AD, Nedza FM, Emm T et al (2010) Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos 38(11):2023\u20132031","journal-title":"Drug Metab Dispos"},{"issue":"s1","key":"16_CR12","first-page":"245","volume":"97","author":"M Talpaz","year":"2012a","unstructured":"Talpaz M, Hamburg SI, Jamieson K et al (2012a) Preliminary safety and efficacy from a phase II stud of ruxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50\u2013100\u00a0\u00d7\u00a0109\/L. Haematologica 97(s1):245 (abstract 0597)","journal-title":"L. Haematologica"},{"key":"16_CR13","doi-asserted-by":"crossref","unstructured":"Talpaz M, Paquette R, Afrin L et al (2012b) Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50\u2013100\u00a0\u00d7\u00a0109\/L): a comparison to patients with normal or high starting platelet counts. Blood 120 (abstract 176) (ASH Annual Meeting Abstracts)","DOI":"10.1182\/blood.V120.21.176.176"},{"issue":"12","key":"16_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86(12):1188\u20131191","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"16_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A (2011) Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365(15):1455\u20131457","journal-title":"N Engl J Med"},{"issue":"s1","key":"16_CR16","first-page":"456","volume":"98","author":"A Vannucchi","year":"2013","unstructured":"Vannucchi A, Cervantes F, Niederwieser D et al (2013) Long-term outcomes from a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF): a 3-year update of COMFORT-II. Haematologica 98(s1):456 (abstract S1111)","journal-title":"Haematologica"},{"issue":"12","key":"16_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u20131127","journal-title":"N Engl J Med"},{"issue":"6","key":"16_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z et al (2012a) Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202\u20131209","journal-title":"Blood"},{"issue":"9","key":"16_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012b) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"key":"16_CR20","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al (2012c) Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 120 (abstract 800) (ASH Annual Meeting Abstracts)","DOI":"10.1182\/blood.V120.21.800.800"},{"issue":"4","key":"16_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2013) The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508\u2013516","journal-title":"Br J Haematol"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-54490-3_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T01:51:27Z","timestamp":1676857887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-54490-3_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9783642544897","9783642544903"],"references-count":21,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-54490-3_16","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"23 April 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}